Fangzhou Inc. Reports Remarkable Growth
Fangzhou Inc. (06086.HK), a renowned leader in Internet healthcare solutions, has announced its financial performance for the fiscal year 2024, showing a total revenue of RMB 2.7 billion. This marks an impressive year-over-year increase of 11.2%. Additionally, the company achieved an adjusted net profit of RMB 17.2 million, reflecting a remarkable 139% growth compared to the previous year.
Dr. Xie Fangmin, founder, Chairman, and CEO of Fangzhou, stated that the ongoing advancements in their healthcare model are pivotal. The company remains committed to harnessing artificial intelligence (AI) and aligning with national healthcare policies to foster a patient-centric ecosystem that drives sustainable growth in China's healthcare sector.
Transforming Healthcare through Technological Innovation
Fangzhou operates under the motto of "AI Powered, Innovation-Driven Growth," believing that technological advancements are essential to their strategic development. In 2024, Fangzhou significantly increased its investment in AI innovations including large language models, big data, and cloud computing. These technologies have improved chronic disease management across their platform, leading to notable user growth. As of December 31, 2024, the Jianke Platform registered 49.2 million users and an increase of 20% in average monthly active users, reaching 10.1 million. A strong repeat purchase rate amongst paying users at 84.7% indicates a high level of engagement with the platform's services.
Enhancing Patient-centered Solutions
To cater to patients managing chronic diseases, Fangzhou successfully integrated an online medical insurance payment system into its platform. This move has made medical services more affordable, demonstrating the company's dedication to improving patient accessibility and care.
Expansion of Physician Network and Business Segments
Fangzhou's strategic expansion in 2024 included strengthening its physician network, which now boasts 223,000 registered physicians. Of these, 59% are affiliated with Class III hospitals, and 39% hold esteemed positions such as associate chief physician or higher. Furthermore, the company has implemented a sales force automation (SFA) system and Social Customer Relationship Management (SCRM) system to better serve physicians in underserved areas.
The company also saw a steady boost in key business segments, with its Online Retail Pharmacy Services revenue increasing by 8.3% to RMB 1.405 billion. Similarly, revenue from Customized Content & Marketing Solutions grew by 20.7% to RMB 105.1 million, highlighting the effectiveness of their tailored services.
Strengthening Supply Chain and Future Outlook
Committed to excellence, Fangzhou has enhanced its pharmaceutical supply chain, fostering partnerships with over 1,500 suppliers and 900 pharmaceutical companies, including both international corporations and domestic leaders. The platform now offers nearly 215,000 drug SKUs to its users, with approximately 62% being prescription medications.
As for future prospects in 2025, Fangzhou aims to reinforce its leadership in online chronic disease management. The company’s objectives include further development of AI capabilities, fostering enhanced engagement from medical professionals and users, optimizing supply chain operations, and investing in talent development to spur innovation and growth.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is a top-tier online chronic disease management platform. With 49.2 million registered users and 223,000 registered doctors on its platform as of December 31, 2024, the company is dedicated to delivering customized medical care and precision medicine to manage chronic diseases effectively.
Frequently Asked Questions
What were Fangzhou Inc.’s revenue and profit growth in 2024?
Fangzhou reported an 11.2% increase in total revenue, amounting to RMB 2.7 billion, and a significant 139% growth in adjusted net profit to RMB 17.2 million.
How has AI impacted Fangzhou’s services?
AI innovations enhanced chronic disease management efficiency and contributed to a 20% increase in average monthly active users, reaching 10.1 million.
What is the current status of Fangzhou's physician network?
Fangzhou's physician network has expanded to 223,000 registered physicians, with a significant percentage affiliated with prestigious hospital classifications.
What new financial strategies did Fangzhou implement for patients?
The company integrated an online medical insurance payment system to improve affordability for chronic disease patients.
What are Fangzhou’s plans for the future?
Looking ahead to 2025, Fangzhou aims to enhance AI capabilities, optimize supply chains, and invest in talent to maintain its market leadership in online chronic disease management.
